Differentiation of innovation strategies based on pharmaceutical licensing agreements: Insight from Korean pharmaceutical firms
暂无分享,去创建一个
[1] Country report (Korea) , 2020, 2020 23rd Conference of the Oriental COCOSDA International Committee for the Co-ordination and Standardisation of Speech Databases and Assessment Techniques (O-COCOSDA).
[2] Chie Hoon Song,et al. Mapping the Patent Landscape in the Field of Personalized Medicine , 2017, Journal of Pharmaceutical Innovation.
[3] Yitao Wang,et al. Obstacles and opportunities in Chinese pharmaceutical innovation , 2017, Globalization and Health.
[4] Sungwoong Hwang,et al. Middle-ground players in dynamic imitative markets: global entry strategies of Korean firms in the biosimilars market , 2017, Technol. Anal. Strateg. Manag..
[5] Jens Leker,et al. Anticipation of converging technology areas — A refined approach for the identification of attractive fields of innovation , 2017 .
[6] John Qi Dong,et al. Being Central Is a Double-Edged Sword: Knowledge Network Centrality and New Product Development in U.S. Pharmaceutical Industry , 2016 .
[7] Seungmin Kim,et al. How knowledge flow affects Korean ICT manufacturing firm performance: a focus on open innovation strategy , 2016, Technol. Anal. Strateg. Manag..
[8] M. Reichman,et al. Open innovation in early drug discovery: roadmaps and roadblocks. , 2016, Drug discovery today.
[9] Wonjoon Kim,et al. Identifying the structure of knowledge networks in the US mobile ecosystems: patent citation analysis , 2016, Technol. Anal. Strateg. Manag..
[10] Taeyong Yang,et al. How technological innovation affects the structure of an industry: entrepreneurship evolution in the biotechnology and pharmaceutical industry since 1980 , 2016, Technol. Anal. Strateg. Manag..
[11] Ulrich A. K. Betz,et al. The Pharmaceutical Industry is Opening Its R&D Boundaries , 2016 .
[12] O. Gassmann,et al. Value Creation in the Pharmaceutical Industry: The Critical Path to Innovation , 2016 .
[13] Munjae Lee. Impact of Corporate Governance on Research and Development Investment in the Pharmaceutical Industry in South Korea , 2015, Osong public health and research perspectives.
[14] A. Yawson,et al. R&D intensity, cross-border strategic alliances, and valuation effects , 2015 .
[15] Thomas Scherngell,et al. R&D internationalisation patterns in the global pharmaceutical industry: evidence from a network analytic perspective , 2015, Technol. Anal. Strateg. Manag..
[16] Peter Robbins,et al. Innovating the Innovation Process: An Organisational Experiment in Global Pharma Pursuing Radical Innovation , 2015 .
[17] M. Rocío Martínez-Torres,et al. Analysis of open innovation communities from the perspective of social network analysis , 2014, Technol. Anal. Strateg. Manag..
[18] L. Trigeorgis,et al. The Role of Growth Options in Explaining Stock Returns , 2014, Journal of Financial and Quantitative Analysis.
[19] Oliver Plum,et al. Comparing knowledge networking in different knowledge bases in Germany , 2011 .
[20] Benjamin Hughes,et al. Knowledge Arbitrage in Global Pharma: A Synthetic View of Absorptive Capacity and Open Innovation , 2010 .
[21] J. DiMasi,et al. Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs , 2010, Clinical pharmacology and therapeutics.
[22] Susie Stephens,et al. Is open innovation the way forward for big pharma? , 2010, Nature Reviews Drug Discovery.
[23] O. Gassmann,et al. Open R&D and Open Innovation: Exploring the Phenomenon , 2009 .
[24] J. Alegre,et al. Analysing the link between export intensity, innovation and firm size in a science-based industry , 2007 .
[25] James Mittra,et al. Life Science Innovation and the Restructuring of the Pharmaceutical Industry: Merger, Acquisition and Strategic Alliance Behaviour of Large Firms , 2007, Technol. Anal. Strateg. Manag..
[26] Nadine Roijakkers,et al. Inter-firm R&D partnering in pharmaceutical biotechnology since 1975: Trends, patterns, and networks , 2006 .
[27] B. Dousset. Innovation and network structural dynamics: Study of the alliance network of a major sector of the biotechnology industry , 2005 .
[28] Amanda Langley,et al. Grand strategies and strategic actions in the pharmaceutical industry 2001–2002 , 2005, Technol. Anal. Strateg. Manag..
[29] Oliver Gassmann,et al. Organizing Pharmaceutical Innovation: From Science‐based Knowledge Creators to Drug‐oriented Knowledge Brokers , 2005 .
[30] Andrew D. James,et al. The Strategic Management of Mergers and Acquisitions in the Pharmaceutical Industry: Developing a Resource-based Perspective , 2002, Technol. Anal. Strateg. Manag..
[31] Massimo Riccaboni,et al. Technological change and network dynamics: Lessons from the pharmaceutical industry , 2001 .
[32] Charles Oppenheim,et al. Patent citation analysis , 1997, Scientometrics.
[33] Kyung-Nam Kang,et al. Influence of government R&D support and inter-firm collaborations on innovation in Korean biotechnology SMEs , 2012 .
[34] V. Chiesa,et al. Organisational modes for Open Innovation in the bio-pharmaceutical industry: An exploratory analysis , 2011 .
[35] H. Chesbrough. The Era of Open Innovation , 2003 .
[36] Vladimir Batagelj,et al. Centrality in Social Networks , 1993 .
[37] Jinjoo Lee,et al. Innovation strategy of local pharmaceutical firms in Korea: a multivariate analysis , 1989 .
[38] L. Freeman,et al. Centrality in social networks: ii. experimental results☆ , 1979 .